Completed PHASE2 INTERVENTIONAL 4-arm NCT01336166

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Sponsor: Shanghai Institute Of Biological Products

Conditions Influenza

Interventions Placebo control split-virion, non-adjuvanted H1N1 vaccine of 15 μg split-virion, non-adjuvanted H1N1 vaccine of 30 μg split-virion, non-adjuvanted H1N1 vaccine of 45 μg

Updated 6 times since 2017 Last updated: Sep 8, 2018 Started: Jul 31, 2009 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01336166, this PHASE2 trial focuses on Influenza and remains completed. Sponsored by Shanghai Institute Of Biological Products, it has been updated 6 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Oct 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Institute Of Biological Products

Data source: Shanghai Institute Of Biological Products

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China